Ensysce Biosciences, Inc.
ENSC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001716947
In the last 90 days, Ensysce Biosciences, Inc. insiders filed 1 open-market purchase and 0 sales; 18 institutions reported holding it in 13F filings for Q2 2026, worth $261.1K in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Ensysce Biosciences, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 1 filing
- 1 insider, $444.2K in total
- Open-market sells
- 0 filings
- Insiders trading
- 1
- Net value
- +$444.2K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Ensysce Biosciences, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Gower Bob G | Director | 916,740 | Aug 18, 2026 | 1 |
| Martin Steven Robert | Director | – | Jun 27, 2022 | 0 |
| Chang William H | Director, 10% Owner | 2,242,189Indirect | Jun 27, 2022 | 0 |
| Rauch Lee M. | Director | – | Jun 27, 2022 | 0 |
| Benton Andrew | Director | – | Jun 27, 2022 | 0 |
| Levin Adam | Director | – | Jun 27, 2022 | 0 |
| Rosebraugh Curtis | Director | – | Jun 27, 2022 | 0 |
| Kirkpatrick Lynn | Chief Executive Officer | 381,851 | May 27, 2022 | 0 |
| Humphrey David Carl | Chief Financial Officer | 50,000 | Feb 24, 2022 | 0 |
| Birkett Kevin Geoffrey | Chief Commercial Officer | – | Feb 24, 2022 | 0 |
| Pestano Linda | Chief Development Officer | – | Feb 4, 2022 | 0 |
| Schmidt William K | Chief Medical Officer | – | Jul 2, 2021 | 0 |
| Wright Richard Chester | Chief Business Officer | – | Jul 2, 2021 | 0 |
| Silvers Daniel B. | 10% Owner | – | Jul 1, 2021 | 0 |
| MLCP GLL Funding LLC | 10% Owner | – | Jul 1, 2021 | 0 |
| Matthews Lane Capital Partners LLC | 10% Owner | – | Jul 1, 2021 | 0 |
| Weil A Lorne | 10% Owner | – | Jul 1, 2021 | 0 |
| Peng George | Other: Former officer | – | Jul 1, 2021 | 0 |
| Carrera Eric | Other: Former officer | – | Jul 1, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 18, 2026 (view filing)6:06 AM ET | Apr 23-Aug 7 | 117 daysLate | Gower Bob GDirector | PPurchase | +908.6K | $0.4888 | +$444.2K | +11,181.6%916.7K after | 2 lots |
| Mar 6, 2023 (view filing)4:33 PM ET | Mar 2 | 4 days | Gower Bob GDirector | PPurchase | +90.3K | $0.4883 | +$44.1K | +8.0%1.22M after | |
| Mar 2, 2023 (view filing)3:45 PM ET | Feb 28-Mar 1 | 2 days | Gower Bob GDirector | PPurchase | +379.3K | $0.4808 | +$182.4K | +50.4%1.13M after | 2 lots |
| Feb 1, 2023 (view filing) | Dec 9, 2022 | 54 daysLate | Gower Bob GDirector | PPurchase | +357.1K | $1.40 | +$500.0K | +90.2%753.1K after | |
| May 27, 2022 (view filing)2:05 PM ET | May 25-26 | 2 days | Kirkpatrick LynnChief Executive Officer | PPurchase | +97.0K | $0.4979 | +$48.3K | +34.1%381.9K after | 2 lots |